AU2003282722A1 - Therapeutic compositions - Google Patents
Therapeutic compositionsInfo
- Publication number
- AU2003282722A1 AU2003282722A1 AU2003282722A AU2003282722A AU2003282722A1 AU 2003282722 A1 AU2003282722 A1 AU 2003282722A1 AU 2003282722 A AU2003282722 A AU 2003282722A AU 2003282722 A AU2003282722 A AU 2003282722A AU 2003282722 A1 AU2003282722 A1 AU 2003282722A1
- Authority
- AU
- Australia
- Prior art keywords
- therapeutic compositions
- therapeutic
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41569802P | 2002-10-02 | 2002-10-02 | |
| US60/415,698 | 2002-10-02 | ||
| PCT/US2003/031717 WO2004030634A2 (en) | 2002-10-02 | 2003-10-02 | Therapeutic compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003282722A8 AU2003282722A8 (en) | 2004-04-23 |
| AU2003282722A1 true AU2003282722A1 (en) | 2004-04-23 |
Family
ID=32069900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003282722A Abandoned AU2003282722A1 (en) | 2002-10-02 | 2003-10-02 | Therapeutic compositions |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003282722A1 (en) |
| WO (1) | WO2004030634A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005003788A1 (en) | 2005-01-19 | 2006-07-20 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | siRNA molecules for the treatment of blood vessels |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| KR101141544B1 (en) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | Multi-conjugate of siRNA and preparing method thereof |
| US9200276B2 (en) | 2009-06-01 | 2015-12-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
| MX2017016088A (en) | 2015-06-15 | 2018-04-11 | Mpeg La Llc | Defined multi-conjugate oligonucleotides. |
| WO2017035278A1 (en) | 2015-08-24 | 2017-03-02 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
| JP7183167B2 (en) | 2017-02-06 | 2022-12-05 | エムペグ エルエイ リミテッド ライアビリティ カンパニー | Multimeric oligonucleotides with reduced renal clearance |
| WO2024059618A2 (en) | 2022-09-13 | 2024-03-21 | Arsenal Biosciences, Inc. | Immune cells having co-expressed tgfbr shrnas |
| WO2024059824A2 (en) | 2022-09-16 | 2024-03-21 | Arsenal Biosciences, Inc. | Immune cells with combination gene perturbations |
-
2003
- 2003-10-02 WO PCT/US2003/031717 patent/WO2004030634A2/en not_active Application Discontinuation
- 2003-10-02 AU AU2003282722A patent/AU2003282722A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004030634A3 (en) | 2004-09-23 |
| WO2004030634A2 (en) | 2004-04-15 |
| AU2003282722A8 (en) | 2004-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AUPS146402A0 (en) | Nanofiller compositions | |
| AU2003291103A1 (en) | Pharmaceutical composition | |
| AU2003279340A1 (en) | Shampoo compositions | |
| AU2003299034A1 (en) | Transdermal compositions | |
| AU2003285288A1 (en) | Composition | |
| AU2003280797A1 (en) | Shampoo composition | |
| AU2003250372A1 (en) | Pharmaceutical composition | |
| AU2003279911A1 (en) | Therapeutic formulations | |
| AU2002950744A0 (en) | Composition | |
| AU2003235708A1 (en) | Polytartrate composition | |
| AU2003226487A1 (en) | Formulation | |
| AU2003247005A1 (en) | Therapy combination | |
| AU2003245794A1 (en) | Glycosaminoglycan-dnase combination therapy | |
| AU2003269904A1 (en) | Antigen-polymer compositions | |
| AU2003208411A1 (en) | Anti-glycolytic composition | |
| AU2003217110A1 (en) | Novel formulation | |
| AU2002365093A1 (en) | Therapeutic compositions | |
| AU2003215150A1 (en) | Therapeutic compounds | |
| AUPR600601A0 (en) | Therapeutic compositions | |
| AU2003282722A1 (en) | Therapeutic compositions | |
| GB0222945D0 (en) | Therapeutic compositions | |
| AU2003284460A1 (en) | Medicinal composition | |
| AU2003301902A1 (en) | Cosmetic compositions | |
| AU2003280799A1 (en) | Medicinal composition | |
| AU2003216503A1 (en) | Stable pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |